Details for Patent: 12,263,153

« Back to Dashboard

Which drugs does patent 12,263,153 protect, and when does it expire?

Patent 12,263,153 protects SYNJARDY XR, JARDIANCE, and SYNJARDY, and is included in three NDAs.

This patent has fifty-four patent family members in fourteen countries.

Summary for Patent: 12,263,153

Title:	Pharmaceutical composition, methods for treating and uses thereof
Abstract:	The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
Inventor(s):	Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen Woerle
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/831,460
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,263,153

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No						TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No						TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-003	Dec 9, 2016		RX	Yes	No						TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes						TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-001	Aug 1, 2014	AB	RX	Yes	No						USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014	AB	RX	Yes	Yes						USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION

International Family Members for US Patent 12,263,153

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017233889
Australia	2017357589
Australia	2022246392
Australia	2023203321
Australia	2024216447
Brazil	112018016001